AC Immune Reports Positive Safety & Immunogenicity at week-100 in Part 1 of VacSYn Phase 2 Trial of ACI-7104
AC Immune reported positive week-100 results from Part 1 of the VacSYn Phase 2 trial of ACI-7104 in early-stage Parkinson's disease, with all primary endpoints of safety, tolerability and immunogenicity met. 100% of treated patients developed antibodies against the a-syn target after three immunizations, with robust antibody penetration into the CSF and preliminary signals of target engagement.
Key figures
- Drug Name
- ACI-7104
- Phase Of Trial
- Phase 2
- Trial name
- VacSYn
- Data timepoint
- week-100
- Patients treated
- 25
- Placebo patients
- 9
- Fda meeting timing
- early 2027
- Patients randomized
- 34
- Immunogenicity response rate
- 100%
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.